See more : Strategic Education, Inc. (STRA) Income Statement Analysis – Financial Results
Complete financial analysis of STAAR Surgical Company (STAA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of STAAR Surgical Company, a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- Fortis Inc. (FTS) Income Statement Analysis – Financial Results
- PROOF Acquisition Corp I WT (PACI-WT) Income Statement Analysis – Financial Results
- ClearOne, Inc. (CLRO) Income Statement Analysis – Financial Results
- Zhejiang Jiuzhou Pharmaceutical Co., Ltd (603456.SS) Income Statement Analysis – Financial Results
- Incap Limited (INCAP.BO) Income Statement Analysis – Financial Results
STAAR Surgical Company (STAA)
About STAAR Surgical Company
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 322.42M | 284.39M | 230.47M | 163.46M | 150.19M | 123.95M | 90.61M | 82.43M | 77.12M | 74.99M | 72.22M | 63.78M | 62.77M | 54.96M | 75.35M | 74.89M | 59.36M | 56.28M | 51.30M | 51.69M | 50.46M | 48.25M | 50.24M | 53.99M | 59.00M | 54.20M | 42.50M | 42.20M | 34.70M | 27.40M | 20.10M | 10.20M | 4.30M | 4.50M | 4.50M | 6.80M |
| Cost of Revenue | 69.76M | 61.01M | 51.84M | 45.10M | 38.23M | 32.44M | 26.33M | 24.06M | 24.40M | 26.16M | 21.91M | 19.49M | 20.40M | 19.88M | 33.45M | 34.79M | 30.10M | 29.85M | 27.52M | 25.54M | 22.62M | 24.10M | 28.20M | 22.60M | 18.70M | 14.10M | 6.80M | 7.90M | 6.90M | 4.80M | 3.10M | 2.40M | 2.00M | 2.00M | 7.20M | 8.00M |
| Gross Profit | 252.65M | 223.38M | 178.64M | 118.36M | 111.95M | 91.51M | 64.28M | 58.37M | 52.72M | 48.82M | 50.31M | 44.29M | 42.37M | 35.08M | 41.89M | 40.11M | 29.27M | 26.43M | 23.79M | 26.14M | 27.84M | 24.15M | 22.03M | 31.39M | 40.30M | 40.10M | 35.70M | 34.30M | 27.80M | 22.60M | 17.00M | 7.80M | 2.30M | 2.50M | -2.70M | -1.20M |
| Gross Profit Ratio | 78.36% | 78.55% | 77.51% | 72.41% | 74.54% | 73.83% | 70.94% | 70.81% | 68.36% | 65.11% | 69.67% | 69.44% | 67.50% | 63.82% | 55.60% | 53.55% | 49.30% | 46.97% | 46.36% | 50.58% | 55.17% | 50.05% | 43.86% | 58.14% | 68.31% | 73.99% | 84.00% | 81.28% | 80.12% | 82.48% | 84.58% | 76.47% | 53.49% | 55.56% | -60.00% | -17.65% |
| Research & Development | 44.40M | 35.98M | 33.86M | 31.92M | 25.30M | 22.03M | 19.12M | 20.29M | 14.76M | 12.36M | 6.71M | 6.44M | 5.87M | 5.72M | 5.89M | 7.94M | 6.71M | 7.08M | 5.57M | 6.25M | 5.12M | 4.02M | 3.80M | 4.22M | 4.30M | 3.60M | 3.90M | 4.10M | 3.30M | 2.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 72.32M | 54.74M | 44.14M | 33.91M | 29.31M | 24.29M | 20.67M | 22.25M | 19.60M | 18.48M | 18.81M | 17.79M | 15.99M | 14.08M | 15.71M | 15.73M | 12.95M | 9.34M | 9.34M | 9.34M | 9.34M | 0.00 | 8.75M | 8.59M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 107.83M | 88.86M | 67.29M | 45.76M | 45.49M | 38.60M | 28.13M | 28.48M | 23.70M | 25.88M | 23.89M | 21.28M | 17.73M | 17.18M | 24.26M | 27.05M | 23.72M | 19.51M | 19.51M | 19.51M | 19.51M | 0.00 | 20.04M | 21.25M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 180.15M | 143.60M | 111.44M | 79.68M | 74.80M | 62.89M | 48.80M | 50.73M | 43.30M | 44.36M | 42.70M | 39.07M | 33.72M | 31.25M | 39.97M | 42.78M | 36.67M | 33.29M | 29.03M | 30.06M | 29.24M | 25.79M | 28.79M | 43.62M | 27.80M | 25.50M | 19.00M | 17.80M | 15.90M | 13.10M | 14.20M | 11.60M | 12.90M | 6.10M | 0.00 | 0.00 |
| Other Expenses | 0.00 | 1.26M | 967.00K | 396.00K | 703.00K | 715.00K | 628.00K | 470.00K | 759.00K | 381.00K | 486.00K | 822.00K | 0.00 | 700.00K | -238.00K | 9.77M | 0.00 | -331.00K | 0.00 | 0.00 | 0.00 | 1.45M | 0.00 | 3.73M | 4.20M | 4.40M | 3.50M | 2.30M | 1.50M | 1.30M | 900.00K | 800.00K | 600.00K | 500.00K | 900.00K | 1.50M |
| Operating Expenses | 224.55M | 179.58M | 145.30M | 111.59M | 100.10M | 84.92M | 67.91M | 71.02M | 58.06M | 56.85M | 49.61M | 45.51M | 39.59M | 37.68M | 45.62M | 60.49M | 43.39M | 40.04M | 34.60M | 36.30M | 34.36M | 31.26M | 32.59M | 51.57M | 36.30M | 33.50M | 26.40M | 24.20M | 20.70M | 17.10M | 15.10M | 12.40M | 13.50M | 6.60M | 900.00K | 1.50M |
| Cost & Expenses | 294.32M | 240.59M | 197.13M | 156.69M | 138.33M | 117.36M | 94.24M | 95.09M | 82.46M | 83.01M | 71.52M | 65.00M | 59.98M | 57.56M | 79.07M | 95.28M | 73.48M | 69.88M | 62.12M | 61.84M | 56.98M | 55.36M | 60.79M | 74.17M | 55.00M | 47.60M | 33.20M | 32.10M | 27.60M | 21.90M | 18.20M | 14.80M | 15.50M | 8.60M | 8.10M | 9.50M |
| Interest Income | 0.00 | 2.45M | 38.00K | 238.00K | 988.00K | 165.00K | 0.00 | 3.00K | 50.00K | 51.00K | 59.00K | 59.00K | 32.00K | 43.00K | 60.00K | 160.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 270.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 2.45M | 0.00 | 0.00 | 0.00 | 165.00K | 0.00 | 115.00K | 128.00K | 154.00K | 170.00K | 291.00K | 523.00K | 896.00K | 1.33M | 901.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 5.12M | 4.51M | 3.64M | 3.10M | 3.70M | 2.46M | 3.35M | 2.89M | 2.40M | 2.46M | 2.15M | 1.96M | 2.27M | 2.41M | 3.74M | 3.64M | 2.51M | 2.37M | 2.47M | 2.69M | 2.90M | 3.10M | 3.62M | 3.73M | 4.20M | 4.40M | 3.50M | 2.30M | 1.50M | 1.30M | 900.00K | 800.00K | 600.00K | 500.00K | 900.00K | 1.50M |
| EBITDA | 33.22M | 48.31M | 36.98M | 9.86M | 15.55M | 9.06M | -277.00K | -9.66M | -3.08M | -5.14M | 3.44M | 1.75M | 5.49M | -379.00K | 364.00K | -17.13M | -12.19M | -10.88M | -7.32M | -7.34M | -3.62M | -4.01M | -6.93M | -16.45M | 8.20M | 11.00M | 12.80M | 12.40M | 8.60M | 6.80M | 2.80M | -3.80M | -10.60M | -3.60M | -2.70M | -1.20M |
| EBITDA Ratio | 10.30% | 17.59% | 17.33% | 5.51% | 10.70% | 7.98% | -1.21% | -11.27% | -2.76% | -6.85% | 4.70% | 2.54% | 8.10% | -0.28% | 0.10% | -22.15% | -18.54% | -20.45% | -17.06% | -14.63% | -6.12% | -4.81% | 1.54% | -21.19% | 13.39% | 19.00% | 23.06% | 27.96% | 23.05% | 21.90% | 10.45% | -63.73% | -244.19% | -313.33% | -60.00% | -19.12% |
| Operating Income | 28.10M | 43.80M | 33.34M | 6.77M | 11.85M | 6.60M | -3.63M | -12.66M | -5.34M | -8.03M | 700.00K | -1.22M | 2.78M | -2.60M | -3.73M | -20.39M | -14.12M | -13.60M | -10.81M | -10.16M | -6.53M | -7.11M | -17.79M | -20.18M | 4.00M | 6.60M | 9.30M | 10.10M | 7.10M | 5.50M | 1.90M | -4.60M | -11.20M | -4.10M | -3.60M | -2.70M |
| Operating Income Ratio | 8.71% | 15.40% | 14.47% | 4.14% | 7.89% | 5.32% | -4.01% | -15.35% | -6.92% | -10.70% | 0.97% | -1.91% | 4.43% | -4.73% | -4.95% | -27.22% | -23.78% | -24.17% | -21.07% | -19.65% | -12.93% | -14.74% | -35.40% | -37.38% | 6.78% | 12.18% | 21.88% | 23.93% | 20.46% | 20.07% | 9.45% | -45.10% | -260.47% | -91.11% | -80.00% | -39.71% |
| Total Other Income/Expenses | 5.60M | 1.75M | -2.04M | 1.50M | 1.17M | 44.00K | 1.34M | 211.00K | -268.00K | -618.00K | 414.00K | 701.00K | -79.00K | -1.08M | -741.00K | -1.29M | -1.04M | 95.00K | 854.00K | -88.00K | -705.00K | -1.01M | 2.99M | -5.30M | -900.00K | -500.00K | 2.40M | 100.00K | 300.00K | 600.00K | 700.00K | 2.70M | -100.00K | 10.00M | 0.00 | -800.00K |
| Income Before Tax | 33.70M | 45.80M | 31.30M | 8.27M | 13.03M | 6.64M | -2.30M | -12.44M | -5.61M | -8.65M | 1.11M | -519.00K | 2.70M | -3.68M | -4.71M | -21.67M | -15.16M | -13.51M | -9.96M | -10.25M | -7.16M | -8.12M | -18.24M | -25.48M | 3.10M | 6.10M | 11.70M | 10.20M | 7.40M | 6.10M | 2.60M | -1.90M | -11.30M | 5.90M | 0.00 | -3.50M |
| Income Before Tax Ratio | 10.45% | 16.11% | 13.58% | 5.06% | 8.67% | 5.36% | -2.53% | -15.10% | -7.27% | -11.53% | 1.54% | -0.81% | 4.31% | -6.70% | -6.25% | -28.94% | -25.53% | -24.00% | -19.41% | -19.82% | -14.19% | -16.84% | -36.31% | -47.20% | 5.25% | 11.25% | 27.53% | 24.17% | 21.33% | 22.26% | 12.94% | -18.63% | -262.79% | 131.11% | 0.00% | -51.47% |
| Income Tax Expense | 12.35M | 6.80M | 6.80M | 2.35M | -1.02M | 1.67M | -157.00K | -315.00K | 928.00K | -253.00K | 716.00K | 1.24M | 1.36M | 432.00K | 1.49M | 1.52M | 843.00K | 1.54M | 1.24M | 1.06M | 1.13M | 8.96M | -3.55M | -6.58M | 900.00K | 2.00M | 4.30M | 3.30M | -100.00K | -2.20M | 100.00K | 500.00K | 100.00K | 2.60M | 800.00K | 200.00K |
| Net Income | 21.35M | 39.67M | 27.51M | 5.91M | 14.05M | 4.97M | -2.14M | -12.13M | -6.53M | -8.39M | 398.00K | -1.76M | 1.35M | 53.00K | -6.20M | -23.20M | -16.00M | -15.04M | -11.18M | -11.33M | -8.36M | -17.16M | -14.83M | -18.90M | 2.20M | 2.40M | 7.40M | 6.90M | 7.50M | 8.30M | 2.50M | -5.10M | -11.30M | 3.50M | -4.40M | -3.80M |
| Net Income Ratio | 6.62% | 13.95% | 11.94% | 3.62% | 9.35% | 4.01% | -2.36% | -14.71% | -8.47% | -11.19% | 0.55% | -2.76% | 2.15% | 0.10% | -8.23% | -30.97% | -26.95% | -26.73% | -21.78% | -21.93% | -16.56% | -35.56% | -29.53% | -35.01% | 3.73% | 4.43% | 17.41% | 16.35% | 21.61% | 30.29% | 12.44% | -50.00% | -262.79% | 77.78% | -97.78% | -55.88% |
| EPS | 0.44 | 0.83 | 0.52 | 0.13 | 0.32 | 0.11 | -0.05 | -0.30 | -0.17 | -0.22 | 0.01 | -0.05 | 0.04 | 0.00 | -0.19 | -0.79 | -0.57 | -0.60 | -0.47 | -0.58 | -0.47 | -1.00 | -0.87 | -1.23 | 0.15 | 0.18 | 0.57 | 0.50 | 0.55 | 0.84 | 0.21 | -0.50 | -1.22 | 1.44 | -1.59 | -1.52 |
| EPS Diluted | 0.43 | 0.80 | 0.50 | 0.12 | 0.30 | 0.11 | -0.05 | -0.30 | -0.17 | -0.22 | 0.01 | -0.05 | 0.04 | 0.00 | -0.19 | -0.79 | -0.57 | -0.60 | -0.47 | -0.58 | -0.47 | -1.00 | -0.87 | -1.23 | 0.15 | 0.17 | 0.53 | 0.50 | 0.55 | 0.80 | 0.20 | -0.50 | -1.22 | 1.44 | -1.59 | -1.52 |
| Weighted Avg Shares Out | 48.52M | 47.99M | 47.21M | 45.61M | 44.49M | 45.16M | 41.00M | 40.33M | 38.43M | 38.09M | 36.71M | 35.26M | 35.43M | 34.83M | 32.50M | 29.47M | 28.12M | 25.23M | 23.70M | 19.60M | 17.70M | 17.14M | 17.00M | 15.37M | 14.67M | 13.33M | 12.98M | 13.80M | 13.64M | 9.88M | 11.90M | 10.20M | 9.29M | 4.06M | 2.76M | 2.50M |
| Weighted Avg Shares Out (Dil) | 49.43M | 49.38M | 49.46M | 47.95M | 46.90M | 45.26M | 41.00M | 40.33M | 39.26M | 38.09M | 38.61M | 36.25M | 36.88M | 34.83M | 32.50M | 29.47M | 28.12M | 25.23M | 23.70M | 19.60M | 17.70M | 17.16M | 17.00M | 15.37M | 14.67M | 14.12M | 13.96M | 13.80M | 13.64M | 10.38M | 12.50M | 10.20M | 9.29M | 4.06M | 2.76M | 2.50M |
STAAR Surgical: Economic Realities Beginning To Surface, Reiterate Hold
STAAR Surgical Company's Q2 FY'23 earnings missed consensus estimates. The key revenue driver for STAA is its Implantable Collamer Lenses, which saw a 21% YoY increase in unit volumes. Despite potential topline growth, the economic realities and valuation multiples suggest...
STAAR Surgical to Participate in Upcoming Investor Conferences
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced that management will participate in several upcoming investor conferences. STAAR management will participate in the following investor conferences:...
3 ‘Strong Buy' Growth Stocks You Should Be Loading Up On Now
Growth stocks are on a tear this year, and while some names will inevitably cool off in the coming weeks, opportunities will always exist. In my opinion, investors should start taking profits from growth stocks trading above their intrinsic value,...
Why STAAR Surgical Stock Dropped Today
STAAR Surgical beat on earnings but missed on revenue for the second quarter. The implantable lens leader also lowered its full-year revenue guidance amid slower-than-expected growth in the U.S. and broader macro concerns.
STAAR Surgical Company (STAA) Q2 2023 Earnings Call Transcript
STAAR Surgical Company (NASDAQ:STAA ) Q2 2023 Earnings Conference Call August 2, 2023 4:30 PM ET Company Participants Brian Moore - Investor Relations Tom Frinzi - President and Chief Executive Officer Patrick Williams - Chief Financial Officer Conference Call Participants...
Staar Surgical (STAA) Q2 Earnings Beat Estimates
Staar Surgical (STAA) came out with quarterly earnings of $0.40 per share, beating the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.42 per share a year ago.
STAAR Surgical Reports Second Quarter 2023 Results
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today reported financial results for the second quarter ended June 30, 2023. Second Quarter 2023 Overview Net Sales of $92.3...
STAAR Surgical to Report Second Quarter Results on August 2, 2023
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced that it will release financial results for the second quarter ended June 30, 2023 on Wednesday, August 2,...
I See Opportunity In STAAR Surgical
STAAR Surgical is on the cusp of an acceleration in earnings and growth courtesy of its entrance into the US market. It is profitable, generates positive cash flow, and has zero real debt.
2 Stocks With Unstoppable Growth Potential for the Next Decade
These companies get their edge from medical products that are an improvement over existing treatments. Align Technology is building out its manufacturing capacity to expand globally.
Source: https://incomestatements.info
Category: Stock Reports